DK Shivakumar shares new video of road sweeper trucks to clean Bengaluru's streets. Video
Karnataka Deputy Chief Minister DK Shivakumar recently posted on social media about the advanced street‑sweeper trucks fitted with rotating brooms and high‑pressure water jets — a key move toward cleaner roads across Bengaluru. DCM DK Shivakumar inspects trucks equipped with rotating brooms and water jets to urbanise cleaning in Bengaluru city.
The DCM had launched the new, state-of-the-art 'CityCat' cleaning vehicle last week on Sunday. In his post yesterday, he shared a new video of himself reviewing the vehicle and praising the initiative, which is set to reduce dust pollution in the city.
ALSO READ | Bengaluru gets high-tech 'CityCat' cleaning vehicle as DK Shivakumar pushes clean city drive. Video
He said the initiative was an essential upgrade from manual broom cleaning, emphasizing that these mechanized sweepers cover longer stretches with greater efficiency and help cut down on dust pollution.
In his post, Shivakumar underscored that this is more than cosmetic — these machines operate during off‑peak night hours, using GPS‑guided routes to methodically remove dust and debris, reducing both health hazards and maintenance backlogs.
'A world-class city deserves world-class solutions! Reviewed the Roots Road Sweeper today in Bengaluru. This 'Made in India' road sweeper, equipped with high-performance brooms, water jets for dust control, and smart suction is already at work in 40+ countries. Our commitment: A cleaner city, a better #Bengaluru,' he wrote on social media site X, sharing a video of the truck.
Watch the video here:
He concluded with a rallying message: this is part of Bengaluru's broader shift toward cleaner, safer urban living — leveraging technology to serve its citizens better.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
WS Industries to invest Rs4,000cr for 600-acre industrial park at Sunguvarchatram
CHENNAI: WS industries India Ltd plans to invest about $500 million (about Rs 4,000 crore) in developing an industrial park over 600 acres at Sunguvarchatram near Chennai, close to the electronics hub that houses Foxconn and Samsung. The company has acquired 400 acres of land, including around 250 acres, through SARFAESI auction, that belonged to IVRCL which had originally planned an industrial township. It intends to acquire an additional 200 acres of private land from individuals for the park that will house logistics warehouse, data centres and industrial housing among others. 'The focus is to develop and manage Grade A industrial real estate, data centres and logistics and warehouse parks to cater to multinational companies and pan-India players that have industrial facilities in the region,' WSI chairman Nagarajan Seyyadurai told TOI . It will join hands with international consultants to prepare a detailed project report to this effect. The IVRCL land included a defunct nine-hole golf course and WSI plans to regenerate it to become the hub of its industrial park. 'At 0.5 FSI, the company can easily develop 15 million sqft of industrial as well as logistics warehouse space. Given its proximity to the electronics hub, there is huge demand for developed industrial land, ' sources said. The company is in the process of raising around Rs 440 crore fresh capital by placing its shares at Rs 100 a share with promoters and non-promoters including institutions, private entities and individuals. The fresh capital will be deployed for land acquisition and working capital requirements, sources said. The park is located close to the proposed new international airport near Parandur and the existing Oragadam industrial estate and Chennai-Bengaluru expressway. The acquired land has been converted to facilitate multi-use development. WS industries India is now engaged in the EPC business and has executed infrastructure projects worth Rs 650 crore in the past 24 months. It is also in the process of developing a one million sqft IT park on Mount Poonamallee road and the project is in the approval stage. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
The Hindu
2 hours ago
- The Hindu
Month long E-Khata campaign in July: DKS
Deputy Chief Minister and Bengaluru Development Minister D.K. Shivakumar announced that a month-long campaign will be held from July 1 to issue E-Khatas to property owners in the city. Speaking at a first-of-its-kind E-Khata mela at Sahakarnagar, Byatarayanapura Assembly constituency represented by Revenue Minister Krishna Byre Gowda on Sunday, Mr. Shivakumar termed protection of properties against fraudulent transactions through E-Khatas as another 'guarantee' by the Congress government. He said of the over 25 lakh properties in Bengaluru, E-Khatas were issued to 5.34 lakh properties already. 'The E-Khata programme has won a gold medal for e-governance initiative by the Union government. Combined with Nambike Nakshe, under which we have given deemed plan sanctions to over 9,000 buildings online, e-Khata programme is essentially bringing civic services to your doorstep and cutting down on corruption,' he said. The mela in Sahakarnagar saw overwhelming response with over 4,000 tokens issued to E-Khata applicants and 677 final E-Khatas issued at the spot on Sunday. Responding to demands by property owners in the constituency, the mela has been extended to Monday as well. Of the 1.81 lakh properties in Byatarayanapura, over 51,000 properties have been issued E-Khatas. Mr. Shivakumar said that similar E-Khata melas will be held in other Assembly constituencies as well.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Torrent Pharma to acquire JB Pharma from KKR at ₹25,689 cr valuation
In one of the largest pharma deals in the domestic market in recent years, Ahmedabad-based Torrent Pharmaceuticals will acquire a controlling stake in investment firm KKR-backed JB Chemicals and Pharmaceuticals (known as JB Pharma) at an equity valuation of ₹25,689 crore, which will be followed by the merger of the two entities. The deal will be executed in two phases — acquisition of the 46.39 per cent stake held by KKR in JB Pharma at ₹1,600 per share, amounting to ₹11,917 crore, followed by a mandatory open offer to acquire up to 26 per cent of JB Pharma shares from public shareholders at ₹1,639.18 per share. 'In addition to the above, Torrent has also expressed its intent to acquire up to 2.8 per cent of equity shares from certain employees of JB Pharma at the same price per share as KKR,' the company said in a statement on Sunday. The next step in the deal will be a merger between Torrent Pharma and JB Pharma through a scheme of arrangement, under which every shareholder holding 100 shares in JB Pharma will receive 51 shares of Torrent Pharma. The boards of directors of both companies have approved this arrangement. KKR had acquired 54 per cent of JB Pharma in July 2020 from the promoters and founders, the Mody family, for approximately ₹3,100 crore (or ₹745 per share). It sold a part of its stake in March this year through block deals for ₹1,459.8 crore. KKR has earned more than five times on its investment, with around 36 per cent gross IRR. For instance, Torrent Pharma has previously indicated plans to increase its medical representative (MR) strength by 23 per cent by the end of FY26, and the acquisition can aid in manpower augmentation. Torrent Pharma holds a 3.74 per cent share in the domestic market (according to Pharmarack, May 2025), while JB Pharma commands a 1.12 per cent share. Further, consolidation in key international markets is expected to offer greater scalability. Samir Mehta, executive chairman of Torrent Pharma, said they want to build on JB Pharma's heritage and platform for the future. 'Torrent's deep India presence and JB Pharma's fast-growing India business, combined with the CDMO and international footprint, offer immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market and builds a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Torrent has previously taken the inorganic route to grow its business and enter newer segments — in 2013, it acquired Elder Pharma's India-branded business; followed by the dermaceutical business of Zyg Pharma in 2015 and the API plant of Glochem Industries in 2016. Among other major deals, it bought the India-branded business of Unichem in 2017. Its last major acquisition was of skin-care products from Curatio Healthcare in 2022. Torrent Pharma is a highly domestic-focused company, drawing around 55 per cent of its consolidated revenues from the domestic formulations business. India sales grew by 13 per cent in FY25 to ₹6,393 crore. While the company has been outperforming industry growth in the domestic market, it is also planning to increase MR strength by 23 per cent by FY26-end. Torrent has a strong presence in the cardiovascular, gastrointestinal and neurology segments. JB too has prominent cardiac and gastro brands like Cilacar, Metrogyl and Rantac. Torrent is also working on launching GLP-1 products as a day-one launch in FY26. Analysts expect a 15 per cent sales CAGR in domestic formulations for Torrent Pharma over FY25–27. Gaurav Trehan, co-head of Asia Pacific and head of Asia Pacific private equity at KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies.' Nikhil Chopra, chief executive officer and whole-time director of JB Pharma, pointed out that over the past five years, the company has emerged as one of India's fastest-growing pharmaceutical players. 'We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organisations will unlock greater opportunities to enhance healthcare access across our markets,' Chopra said. JB Pharma posted 12 per cent revenue growth in FY25 to ₹3,918 crore, while its EBITDA rose 16 per cent to ₹1,087 crore, and PAT increased 19 per cent to ₹660 crore. Notably, KKR Private equity has invested $2 billion in India in 2024 and recently invested $600 million in Manipal Group via its private credit arm.
